, Charlotte, North Carolina) was used to retrospectively identify patients diagnosed with digoxin toxicity and/or who received digoxin immune fab Feb 9, 2022 · When a large amount of digoxin has been ingested, especially in patients with impaired renal function, hyperkalemia may be present due to release of potassium from skeletal muscle
It is used to treat an overdose of digoxin or digitoxin
Apr 24, 2023 Digoxin Immune Fab This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and
The reconstituted product should be used
2 Indications 3 Side Effects 4 How To Use 5 See Also 6 References Background 1 Fab vial binds 0
Use of digoxin immune Fab is also appropriate following serum digoxin measurement for patients with less elevated serum digoxin levels when associated with
Literature reports have described successful use of digoxin immune fab in managing non-digoxin cardiac glycoside poisonings with oleander leaves , toad venom
Digoxin immune fab is a medication used in the management and treatment of digoxin toxicity
Dose adjustment not necessary but use caution as digoxin immune Fab complex is renally eliminated
This may be calculated if the amount ingested is known or the postdistribution serum drug level is known (round the dose up to the nearest whole vial)
B
Digoxin immune Fab (DigiFab, Digibind) is packaged in a 40-mg vial and must be reconstituted with 4 mL of sterile water for IV injection, furnishing an iso-osmotic solution
Heart failure or atrial fibrillation (afib) may get worse with this drug
1 mg/kg) in healthy children, or ingestion of an amount that can The diluted digoxin immune fab is added to 0
Each vial contains 40 mg of digoxin immune Fab protein and is intended for one time use only as it contains no preservatives; Reconstitute each vial of DIGIFAB with 4 mL of Sterile Water for Injection USP and gently mix to provide a solution containing approximately 10 mg/mL of digoxin immune Fab protein
DIF = patients who received digoxin immune Fab; non-DIF = patients who did not receive digoxin immune Fab; Dx = diagnosis
DIF was evaluated using treatment date, number of vials administered, and total
1% of patients, and an average of 6
Common adverse reactions include hypokalemia, exacerbation of low cardiac output, and rapid ventricular response in patients with atrial fibrillation
Keep vial in outer carton in order to protect from light
; 2017
Vandenplas O, Vandezande LM, Halloy JL, Delwiche JP, Jamart J, Looze Y